Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Identifying PDGFR signaling could enhance treatment strategies for HR+/HER2− breast cancer, improving outcomes.
• The potential therapeutic vulnerability was noted specifically in tumors characterized as SNF4.
• The analysis suggests a shift from one-size-fits-all therapy to subtyping-directed approaches for better patient care.
• This refinement in therapy could enable more effective precision treatment suited to individual tumor profiles.